Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

PURPOSE: Lifirafenib is an investigational, reversible inhibitor of B-RAF(V600E), wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib in patients with B-RAF– or K-RAS/N-RAS–mutated...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Desai, Jayesh, Gan, Hui, Barrow, Catherine, Jameson, Michael, Atkinson, Victoria, Haydon, Andrew, Millward, Michael, Begbie, Stephen, Brown, Michael, Markman, Ben, Patterson, William, Hill, Andrew, Horvath, Lisa, Nagrial, Adnan, Richardson, Gary, Jackson, Christopher, Friedlander, Michael, Parente, Phillip, Tran, Ben, Wang, Lai, Chen, Yunxin, Tang, Zhiyu, Huang, Wendy, Wu, John, Zeng, Dewan, Luo, Lusong, Solomon, Benjamin
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2020
נושאים:
ORIGINAL REPORTS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325368/
https://ncbi.nlm.nih.gov/pubmed/32182156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02654
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים